TABLE 4.
In vitro activities of gepotidacin and comparator agents against 91 Lactobacillus isolates tested under anaerobic conditions using agar dilutiona
| Antimicrobial agent | MIC (μg/mL) |
MIC interpretation (%)b |
||||
|---|---|---|---|---|---|---|
| MIC range | MIC50 | MIC90 | Susceptible | Intermediate | Resistant | |
| Gepotidacin | ≤0.015 to 2 | 0.5 | 1 | NAc | NA | NA |
| Ceftriaxone | ≤8 to 256 | 32 | 64 | NA | NA | NA |
| Clindamycin | ≤0.25 to >8 | ≤0.25 | 4 | 74.7 | 3.3 | 22.0 |
| Imipenem | ≤0.015 to 8 | 0.25 | 2 | 68.1 | 2.2 | 29.7 |
| Metronidazole | ≤0.12 to >16 | >16 | >16 | NA | NA | NA |
| Moxifloxacin | ≤0.06 to >8 | 0.5 | 4 | NA | NA | NA |
| Piperacillin-tazobactam | ≤0.06 to 8 | 1 | 4 | NA | NA | NA |
a
Lactobacillus isolates included Lactobacillus acidophilus (n = 1), Lactobacillus crispatus (n = 3), Lactobacillus fermentum (n = 5), Lactobacillus gasseri (n = 21), Lactobacillus iners (n = 2), Lactobacillus jensenii (n = 6), Lactobacillus plantarum (n = 1), Lactobacillus rhamnosus (n = 19), and Lactobacillus not identified at the species level (n = 33).
b
Clindamycin and imipenem MICs were interpreted using MIC breakpoints published in the CLSI document M45-A3 (22).
c
NA, not available. CLSI M100 MIC breakpoints are not published for this antimicrobial agent.